Brigatinib (Brigatinib) generic drug price revealed: How much does the Laos Lucius version cost?

Brigatinib (Brigatinib), as a targeted drug, is specially used to treat ALK (anaplastic lymphoma kinase) gene mutation-positive non-small cell lung cancer (NSCLC). As a second-generation tyrosine kinase inhibitor (TKI), brigatinib (brigatinib) effectively interferes with the growth and proliferation of cancer cells by specifically inhibiting ALK kinase activity, thereby achieving therapeutic effects.

In China,Brigatinib has been launched and has been included in the medical insurance catalog. Patients can purchase it domestically at a price of about four to five thousand yuan. For specific price information and medical insurance reimbursement policies, it is recommended to consult the local hospital pharmacy for detailed information.

Compared with the domestic market, the price of generic drugs in foreign markets is usually lower. In particular, the price of generic drugs produced by Lucius Pharmaceuticals in Laos is only a few hundred yuan, which is far lower than the domestic price, and its drug ingredients are basically the same as the original drugs.

The main mechanism of action of brigatinib is to prevent the proliferation of tumor cells by inhibiting ALK kinase. ALKGene mutations play a role in promoting tumor growth in non-small cell lung cancer, and Brigatinib (Brigatinib) can effectively target these mutants, thereby interfering with the signaling pathways of cancer cells. In addition, Brigatinib also has good central nervous system (CNS) penetrating ability, so it also shows significant results in the treatment of non-small cell lung cancer with brain metastasis.

Brigatinib is usually used to treat patients with non-small cell lung cancer who are positive for the ALK gene mutation, especially those who are resistant to first-generation ALK inhibitors such as crizotinib. In clinical trials, brigatinib (brigatinib) showed high efficacy and good tolerability. In the ALTAtrial, brigatinib (brigatinib) was used in both treatment-naïve and already resistant patients.All have shown good therapeutic effects, especially in patients with central nervous system metastases, and their disease control capabilities are particularly significant.

However, using brigatinib may also cause some side effects, common ones include nausea, diarrhea, fatigue, rash, and high blood sugar. Serious side effects may include interstitial lung disease (ILD) and pneumonia. During treatment, doctors will adjust the dose or perform symptomatic treatment according to the severity of side effects to ensure the patient's safety and comfort.